Novo Nordisk Raises Guidance Amid Surging Demand for Diabetes, Obesity Drugs
[ad_1] Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its…
Novo Nordisk A/S Series B
Read More
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New Study
[ad_1] Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a…
Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
[ad_1] Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year…